| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N Møller, G Petrany, D Cassidy, W L Sheldon, D G Johnston, M F Lake. Effects of the somatostatin analogue SMS 201-995 (sandostatin) on mouth-to-caecum transit time and absorption of fat and carbohydrates in normal man. Clinical science (London, England : 1979). vol 75. issue 4. 1989-01-26. PMID:3058374. |
after sms 201-995, an enhancement of the increase in blood glucose (8.2 +/- 0.7 vs 4.7 +/- 0.2 mmol/l, p less than 0.01) and inhibition and postponement of the postprandial rise in insulin (27.6 +/- 6.7 vs 9.9 +/- 2.1 m-units/l, p less than 0.05) occurred. |
1989-01-26 |
2023-08-11 |
human |
| S W Lamberts, G F Pieters, H J Metselaar, G L Ong, H S Tan, J C Reub. Development of resistance to a long-acting somatostatin analogue during treatment of two patients with metastatic endocrine pancreatic tumours. Acta endocrinologica. vol 119. issue 4. 1989-01-17. PMID:2849276. |
in the first patient with an insulinoma both the number of hypoglycemic attacks and the increased insulin levels decreased initially, but returned to pretreatment intensity and concentrations within 9 days after the start of therapy with 200-300 micrograms sms 201-995 daily. |
1989-01-17 |
2023-08-11 |
Not clear |
| R Candrina, G Giustin. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients. Journal of endocrinological investigation. vol 11. issue 7. 1988-11-21. PMID:3049768. |
five type ii diabetic patients were studied after secondary failure of oral agents, with and without the addition of the new long-acting somatostatin analogue sms 201-995 to an intermediate-acting insulin regimen. |
1988-11-21 |
2023-08-11 |
Not clear |
| R Candrina, G Giustin. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal profiles in insulin-treated type II diabetic patients. Journal of endocrinological investigation. vol 11. issue 7. 1988-11-21. PMID:3049768. |
our findings indicate that sms 201-995 may have a role as an adjunct to insulin in the management of type ii diabetic patients after secondary failure of oral agents. |
1988-11-21 |
2023-08-11 |
Not clear |
| D J Hadjidakis, P G Halvatsiotis, Y J Ioannou, P J Mavrokefalos, S A Rapti. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas. Diabetes research and clinical practice. vol 5. issue 2. 1988-10-25. PMID:2901329. |
six patients with no residual insulin secretion were connected to the artificial endocrine pancreas (aep) and after the establishment of a steady state overnight they were injected either normal saline or 50 micrograms of sms 201-995 s.c., t.i.d., or 100 micrograms of the same compound b.i.d. |
1988-10-25 |
2023-08-11 |
Not clear |
| D J Hadjidakis, P G Halvatsiotis, Y J Ioannou, P J Mavrokefalos, S A Rapti. The effects of the somatostatin analogue SMS 201-995 on carbohydrate homeostasis of insulin-dependent diabetics as assessed by the artificial endocrine pancreas. Diabetes research and clinical practice. vol 5. issue 2. 1988-10-25. PMID:2901329. |
sms 201-995 analogue appears to have a remarkable antidiabetic activity as shown by the sparing of administered amount of insulin, suppression of counter-insulin hormones and smoothing of blood glucose curve. |
1988-10-25 |
2023-08-11 |
Not clear |
| I Navascues, J Gil, C Pascau, D Senén, E del Pozo, M Serrano-Río. Effect of a long-acting somatostatin derivative SMS 201-995 (sandostatin) on glucose homeostasis in type I diabetes mellitus. Hormone research. vol 29. issue 2-3. 1988-09-16. PMID:2900205. |
the effect of sms 201-995 (50 micrograms s.c.) on glucose control by exogenous insulin has been documented in a series of type i diabetics after stabilization of blood sugar by an artificial pancreas. |
1988-09-16 |
2023-08-11 |
Not clear |
| A S Alberts, G Falkso. Rapid reversal of life-threatening hypoglycaemia with a somatostatin analogue (octreotide). A case report. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. vol 74. issue 2. 1988-09-07. PMID:2899913. |
treatment with octreotide (sms 201-995, sandostatin; sandoz) resulted in immediate sustained improvement of the hypoglycaemia despite persistent high levels of insulin. |
1988-09-07 |
2023-08-11 |
Not clear |
| D C Wilson, D J Carson, R J Quin. Long-term use of somatostatin analogue SMS 201-995 in the treatment of hypoglycaemia due to nesidioblastosis. Acta paediatrica Scandinavica. vol 77. issue 3. 1988-08-11. PMID:2898862. |
subcutaneous somatostatin analogue (sms 201-995) was shown to increase the blood concentrations of glucose and b-hydroxybutyrate while lowering serum insulin levels. |
1988-08-11 |
2023-08-11 |
Not clear |
| R Candrina, A Gussago, G Giustin. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal response to a mixed meal in acromegalic patients. Journal of endocrinological investigation. vol 11. issue 1. 1988-06-09. PMID:2896207. |
we investigated in 6 acromegalic patients the acute effects on glucose tolerance and insulin secretion of a single sc injection of the somatostatin analogue sms 201-995, performed 4 h before a mixed meal with xylose administration. |
1988-06-09 |
2023-08-11 |
Not clear |
| R Candrina, A Gussago, G Giustin. Effect of a new long-acting somatostatin analogue (SMS 201-995) on glycemic and hormonal response to a mixed meal in acromegalic patients. Journal of endocrinological investigation. vol 11. issue 1. 1988-06-09. PMID:2896207. |
the decrease of serum growth hormone levels, together with partial glucagon inhibition and, more important, a slowing of intestinal absorptive processes, counterbalanced the inhibitory action of sms 201-995 on insulin secretion, and no deterioration in carbohydrate tolerance could be demonstrated. |
1988-06-09 |
2023-08-11 |
Not clear |
| R Oosterom, T Verleun, P Uitterlinden, H A Bruining, G J Bruining, L Verschoor, S W Lambert. Studies on insulin secretion by monolayer cultures of normal and tumorous human pancreatic cells. Effects of glucose, somatostatin and SMS 201-995. Journal of endocrinological investigation. vol 10. issue 6. 1988-04-15. PMID:2894388. |
in the present study we investigated in vitro the regulation, the degree of autonomy and the sensitivity to natural somatostatin and its analog sms 201-995 of insulin secretion by monolayer cultures of human pancreatic cells obtained from patients with insulinomas and from a newborn with nesidioblastosis. |
1988-04-15 |
2023-08-11 |
human |
| R Oosterom, T Verleun, P Uitterlinden, H A Bruining, G J Bruining, L Verschoor, S W Lambert. Studies on insulin secretion by monolayer cultures of normal and tumorous human pancreatic cells. Effects of glucose, somatostatin and SMS 201-995. Journal of endocrinological investigation. vol 10. issue 6. 1988-04-15. PMID:2894388. |
native somatostatin (srif) and the synthetic analog sms 201-995 inhibited insulin secretion from all cultures. |
1988-04-15 |
2023-08-11 |
human |
| A W Kung, J T Ma, C Wang, K H Fu, K S Lam, R T Yeung, J Boe. Prevention of hypoglycaemia in a patient with pancreatic microadenomatosis by a long-acting somatostatin analogue SMS 201-995. Clinical endocrinology. vol 27. issue 4. 1988-04-01. PMID:2893673. |
acute suppression of insulin secretion from pancreatic insulinomas by long-acting somatostatin analogue sms 201-995 has been documented. |
1988-04-01 |
2023-08-11 |
Not clear |
| W P Hopman, R G Wolberink, C B Lamers, J H Van Tongere. Treatment of the dumping syndrome with the somatostatin analogue SMS 201-995. Annals of surgery. vol 207. issue 2. 1988-03-07. PMID:2893592. |
in late dumpers 50 micrograms sms 201-995 reduced peak plasma insulin after oral glucose from 173 +/- 16 mu/l during placebo to 35 +/- 9 mu/l during sms 201-995 (p less than 0.05) and increased individual plasma glucose nadirs from 1.9 +/- 0.3 mmol/l to 7.5 +/- 3.3 mmol/l (p less than 0.01). |
1988-03-07 |
2023-08-11 |
Not clear |
| S W Lambert. A guide to the clinical use of the somatostatin analogue SMS 201-995 (Sandostatin). Acta endocrinologica. Supplementum. vol 286. 1988-02-17. PMID:2892338. |
sms 201-995 (sandostatin) is an octapeptide which differs in its action from native somatostatin in four ways: 1) it inhibits gh hormone secretion in preference to insulin secretion; 2) it can be administered subcutaneously or even orally; 3) it is long-acting (t1/2 after sc administration 113 min), and 4) there is no rebound hypersecretion of hormones when the effect of the analogue lingers off. |
1988-02-17 |
2023-08-11 |
Not clear |
| G F Pieters, P A van Liessum, A G Smals, J A van Gennep, T J Benraad, P W Kloppenbor. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Acta endocrinologica. Supplementum. vol 286. 1988-02-17. PMID:2892339. |
the postprandial rise of insulin levels was reversed by sms, leading to a more pronounced postprandial rise of glucose, whereas the postprandial secretion of glucagon was also reversed by sms. |
1988-02-17 |
2023-08-11 |
Not clear |
| G F Pieters, P A van Liessum, A G Smals, J A van Gennep, T J Benraad, P W Kloppenbor. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses. Acta endocrinologica. Supplementum. vol 286. 1988-02-17. PMID:2892339. |
the rise of glucose levels during oral glucose loading was similar before and during sms, despite a strong inhibitory effect of the drug on the insulin rise after glucose loading. |
1988-02-17 |
2023-08-11 |
Not clear |
| S R George, R A Hegele, G N Burro. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones. Clinical and investigative medicine. Medecine clinique et experimentale. vol 10. issue 4. 1987-10-27. PMID:2888554. |
growth hormone concentrations remained significantly suppressed below placebo control for up to 24 hours after a single dose of sms 201-995, but the inhibitory effects on insulin and c-peptide concentrations were limited to 2 hours. |
1987-10-27 |
2023-08-11 |
Not clear |
| L Verschoor, P Uitterlinden, S W Lamberts, E Del Poz. On the use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clinical endocrinology. vol 25. issue 5. 1987-10-15. PMID:2887309. |
in two of the three patients sms 201-995 suppressed circulating insulin levels by more than 50% and increased plasma glucose to hyperglycaemic levels for 6-8 h after a single injection. |
1987-10-15 |
2023-08-11 |
Not clear |